Mayne Pharma Group announced the launch of TOLSURA (SUBA-itraconazole) 65mg capsule in the United States. TOLSURA is a new formulation of itraconazole indicated for the treatment of systemic fungal infections including blastomycosis (pulmonary and extrapulmonary), histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis) and aspergillosis (pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy).
The company has also completed the recruitment and training of a specialized field sales team who are now promoting the benefits of TOLSURA to infectious disease physicians.
These serious infections most commonly occur in vulnerable or immunocompromised patients, for example, those with a history of cancer, transplants (solid organ or bone marrow), HIV/AIDS, or chronic rheumatic disorders, and are often associated with high mortality rates or long-term health issues.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
The company received US Food and Drug Administration (FDA) approval for TOLSURA in December 2018.
"We are very pleased to launch TOLSURA - a new formulation of itraconazole incorporating Mayne Pharma's proprietary SUBA-technology to improve the bioavailability of poorly soluble drugs,” Mayne Pharma's CEO, Mr. Scott Richards said. “TOLSURA provides a new treatment option for patients and physicians fighting these life-threatening fungal infections. This launch has enabled Mayne Pharma to establish a new institutional sales team focused on hospital based infectious disease specialists. We look forward to bringing further specialty product innovations to market over the coming years with our pipeline of products under development."